Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437437 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
A Phase 1 study of Tumors, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 3
- Study locations
NCT00437437: Completed Phase 1 study of Tumors, sponsored by Bristol-Myers Squibb.
NCT00437437 is a Phase 1 study of Tumors that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 29 participants, below the 198-participant average among 20 other Tumors trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00437437, a Phase 1 study of Tumors, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this trial is to determine the effect of food versus a fasted state on single-dose pharmacokinetics of BMS-540215, the active metabolite of Brivanib alaninate
Conditions Studied
Interventions
- DRUG Brivanib
Study Locations (3)
Massachusetts
- Dana-Farber Harvard Cancer Care - Boston
Michigan
- Wayne State University - Detroit
North Carolina
- Duke University Medical Center-Dept Of Medicine - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2000-05 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
What the finished NCT00437437 record still lists
NCT00437437 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 198-participant average among 20 other Tumors trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Brivanib is the first listed.
NCT00437437 reports a single indexed study location in Massachusetts, Michigan, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00437437 about?
NCT00437437 is a clinical study titled "A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)". The purpose of this trial is to determine the effect of food versus a fasted state on single-dose pharmacokinetics of BMS-540215, the active metabolite of Brivanib alaninate
What is the current status of trial NCT00437437?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2000-05. Estimated completion is 2013-02.
What conditions does trial NCT00437437 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT00437437?
The interventions under investigation include: Brivanib (DRUG).
Who is sponsoring clinical trial NCT00437437?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00437437 being conducted?
This trial has 3 study locations across Massachusetts, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00437437's enrollment target sits among peer trials
29 15th of 20 higher than 6 of 20 other Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia